Cantor Fitzgerald Maintains Overweight on ADMA Biologics, Raises Price Target to $6
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on ADMA Biologics and raises the price target from $5 to $6.
August 10, 2023 | 4:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating on ADMA Biologics and raises the price target from $5 to $6, which could lead to a positive market reaction.
The raised price target by Cantor Fitzgerald indicates a positive outlook for ADMA Biologics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100